| Literature DB >> 30987856 |
Jianghong Deng1, Nathalie E Chalhoub2, Catherine M Sherwin3, Caifeng Li4, Hermine I Brunner5.
Abstract
Glucocorticoids are potent anti-inflammatory and immunosuppressant medications and remain the mainstay of systemic lupus erythematosus (SLE) therapy. The potency of a specific glucocorticoid, i.e., the dose of glucocorticoid that is required to produce a specific effect, is dependent on its pharmacokinetic (PK) and pharmacodynamic (PD) properties. In this review, we summarize the PK/PD properties of commonly used glucocorticoids in an attempt to better delineate their role in the management of children with childhood-onset SLE (cSLE). We also address glucocorticoid side effects as these play a major role when deciding on the dose, frequency, and duration of use. A better understanding of the pharmacology of glucocorticoids appears useful to achieve improved outcomes in the management of cSLE.Entities:
Keywords: Childhood-onset systemic lupus erythematosus; Glucocorticoids; Pharmacodynamics; Pharmacokinetics
Mesh:
Substances:
Year: 2019 PMID: 30987856 PMCID: PMC6744986 DOI: 10.1016/j.semarthrit.2019.03.010
Source DB: PubMed Journal: Semin Arthritis Rheum ISSN: 0049-0172 Impact factor: 5.532